These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 37349360)

  • 1. Enteral administration of the protease inhibitor gabexate mesilate preserves vascular function in experimental trauma/hemorrhagic shock.
    J D Moreira N; Dos Santos F; Li JB; Aletti F; Irigoyen MCC; Kistler EB
    Sci Rep; 2023 Jun; 13(1):10148. PubMed ID: 37349360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enteral gabexate mesilate improves volume requirements and autonomic cardiovascular function after experimental trauma/hemorrhagic shock in the absence of blood reperfusion.
    Dos Santos F; Li JB; Moreira NJ; Mazor R; Aletti F; Kistler EB
    Am J Transl Res; 2022; 14(10):7391-7402. PubMed ID: 36398214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gabexate mesilate, a synthetic protease inhibitor, attenuates endotoxin-induced pulmonary vascular injury by inhibiting tumor necrosis factor production by monocytes.
    Murakami K; Okajima K; Uchiba M; Okabe H; Takatsuki K
    Crit Care Med; 1996 Jun; 24(6):1047-53. PubMed ID: 8681572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gabexate mesilate, a synthetic protease inhibitor, prevents compression-induced spinal cord injury by inhibiting activation of leukocytes in rats.
    Taoka Y; Okajima K; Uchiba M; Murakami K; Kushimoto S; Johno M; Naruo M; Okabe H; Takatsuki K
    Crit Care Med; 1997 May; 25(5):874-9. PubMed ID: 9187610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enteral Tranexamic Acid Decreases Proteolytic Activity in the Heart in Acute Experimental Hemorrhagic Shock.
    Aletti F; Santamaria M; Chin K; Mazor R; Kistler EB
    J Cardiovasc Pharmacol Ther; 2019 Sep; 24(5):484-493. PubMed ID: 31035788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of enteral enzymes by enteroclysis with nafamostat mesilate reduces neutrophil activation and transfusion requirements after hemorrhagic shock.
    Doucet JJ; Hoyt DB; Coimbra R; Schmid-Schönbein GW; Junger WG; Paul L W; Loomis WH; Hugli TE
    J Trauma; 2004 Mar; 56(3):501-10; discussion 510-1. PubMed ID: 15128119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continuous enteral protease inhibition as a novel treatment for experimental trauma/hemorrhagic shock.
    Aletti F; DeLano FA; Maffioli E; Mu H; Schmid-Schönbein GW; Tedeschi G; Kistler EB
    Eur J Trauma Emerg Surg; 2022 Jun; 48(3):1579-1588. PubMed ID: 33483765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel thermosensitive in-situ gel of gabexate mesilate for treatment of traumatic pancreatitis: An experimental study.
    Gao HJ; Song Q; Lv FQ; Wang S; Wang YR; Luo YK; Mei XG; Tang J
    J Huazhong Univ Sci Technolog Med Sci; 2015 Oct; 35(5):707-711. PubMed ID: 26489626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gabexate mesilate inhibits the expression of HMGB1 in lipopolysaccharide-induced acute lung injury.
    Hidaka S; Iwasaka H; Hagiwara S; Noguchi T
    J Surg Res; 2011 Jan; 165(1):142-50. PubMed ID: 19766246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of therapeutic effects of gabexate mesilate on the hepatic encephalopathy in rats with acute and chronic hepatic failure.
    Hsu CY; Lee FY; Huo TI; Chan CY; Huang HC; Lin HC; Chang CC; Teng TH; Wang SS; Lee SD
    J Gastroenterol Hepatol; 2010 Jul; 25(7):1321-8. PubMed ID: 20594263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protease activity increases in plasma, peritoneal fluid, and vital organs after hemorrhagic shock in rats.
    Altshuler AE; Penn AH; Yang JA; Kim GR; Schmid-Schönbein GW
    PLoS One; 2012; 7(3):e32672. PubMed ID: 22479334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enteral tranexamic acid attenuates vasopressor resistance and changes in α1-adrenergic receptor expression in hemorrhagic shock.
    Santamaria MH; Aletti F; Li JB; Tan A; Chang M; Leon J; Schmid-Schönbein GW; Kistler EB
    J Trauma Acute Care Surg; 2017 Aug; 83(2):263-270. PubMed ID: 28422915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gabexate mesilate, a synthetic protease inhibitor, attenuates carbon tetrachloride-induced liver injury in rats.
    Mikami K; Goto T; Miura K; Ohshima S; Yoneyama K; Lin JG; Watanabe D; Segawa D; Kataoka E; Shibuya T; Watanabe S
    J Gastroenterol; 2005 Mar; 40(3):260-5. PubMed ID: 15830285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gabexate mesilate, a synthetic protease inhibitor, reduces ischemia/reperfusion injury of rat liver by inhibiting leukocyte activation.
    Harada N; Okajima K; Kushimoto S
    Crit Care Med; 1999 Sep; 27(9):1958-64. PubMed ID: 10507625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serine proteases are involved in the pathogenesis of trauma-hemorrhagic shock-induced gut and lung injury.
    Deitch EA; Shi HP; Lu Q; Feketeova E; Xu DZ
    Shock; 2003 May; 19(5):452-6. PubMed ID: 12744489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatocyte protection by a protease inhibitor against ischemia/reperfusion injury of human liver.
    Kim YI; Hwang YJ; Song KE; Yun YK; Lee JW; Chun BY
    J Am Coll Surg; 2002 Jul; 195(1):41-50. PubMed ID: 12113544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of synthetic protease inhibitor gabexate mesilate on the attenuation of ischemia/reperfusion injury in canine kidney autotransplantation.
    Inoue S; Sugitani A; Yamamoto H; Kitada H; Motoyama K; Okabe Y; Ohta M; Yoshida J; Nishiyama K; Tanaka M
    Surgery; 2005 Feb; 137(2):216-24. PubMed ID: 15674204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of gabexate mesilate on ischemia-reperfusion-induced testicular injury in rats.
    Gezici A; Ozturk H; Buyukbayram H; Ozturk H; Okur H
    Pediatr Surg Int; 2006 May; 22(5):435-41. PubMed ID: 16557390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gabexate mesilate inhibits colon cancer growth, invasion, and metastasis by reducing matrix metalloproteinases and angiogenesis.
    Yoon WH; Jung YJ; Kim TD; Li G; Park BJ; Kim JY; Lee YC; Kim JM; Park JI; Park HD; No ZS; Lim K; Hwang BD; Kim YS
    Clin Cancer Res; 2004 Jul; 10(13):4517-26. PubMed ID: 15240544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of intraluminal pancreatic enzymes with nafamostat mesilate improves clinical outcomes after hemorrhagic shock in swine.
    Kim HD; Malinoski DJ; Borazjani B; Patel MS; Chen J; Slone J; Nguyen XM; Steward E; Schmid-Schonbein GW; Hoyt DB
    J Trauma; 2010 May; 68(5):1078-83. PubMed ID: 20453762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.